Intrahepatic Cholangiocarcinoma Overview

Cancer that occurs in the parts of the bile ducts that are within the liver is called intrahepatic cholangiocarcinoma (ICC), also known as intrahepatic bile duct cancer. ICC is a rare disease and makes up about 10% of all cholangiocarcinoma.

“Intrahepatic Cholangiocarcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.

The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as – Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment 
• Intrahepatic Cholangiocarcinoma Emerging therapies such as – XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.   
• Basilea Pharmaceutica initiated a Pivotal Study of Derazantinib in Patients WithInoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications.

Route of Administration

Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment

• Intrahepatic Cholangiocarcinoma Assessment by Product Type
• Intrahepatic Cholangiocarcinoma By Stage and Product Type
• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
• Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
• Intrahepatic Cholangiocarcinoma by Stage and Molecule Type

DelveInsight’s Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Intrahepatic Cholangiocarcinoma Therapeutics Market include:

Key companies developing therapies for the Intrahepatic Cholangiocarcinoma are – Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array BioPharma, and others

Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:

• XmAb®22841: Xencor, Inc.
• RLY-4008: Relay Therapeutics
• KIN-3248: Kinnate Biopharma
• FT-2102: Forma Therapeutics, Inc.
• SD 101: TriSalus Life Sciences
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
• VG161: Virogin Biotech Ltd
• Derazantinib: Basilea Pharmaceuticals

Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight

Intrahepatic Cholangiocarcinoma Pipeline Analysis:

The Intrahepatic Cholangiocarcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Intrahepatic Cholangiocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
• Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies

Intrahepatic Cholangiocarcinoma Pipeline Market Drivers

• Rising incidence of Cholangiocarcinoma. ICC makes up 8–10% of all Cholangiocarcinoma
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma Pipeline Market Barriers

• Poor prognosis and diagnosis of the disease
• Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication.

Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others
• Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others
• Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
• Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers 

Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com